MedTrace Logo

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

NCT05661357 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2024-04-17

No results posted yet for this study

Summary

Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures

Conditions

Interventions

DRUG

Disitamab Vedotin Combined With Fruquintinib

Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)

Sponsors & Collaborators

  • Huangshi Central Hospital

    collaborator OTHER

  • The First People's Hospital of Tianmen

    collaborator UNKNOWN

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Hubei Cancer Hospital

    collaborator OTHER

  • Zhongnan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-01-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05661357 on ClinicalTrials.gov